Following the NDA submission for icotrokinra treatment of adults and adolescents with moderate to severe plaque psoriasis to ...

Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer ...

The highest dose of Eli Lilly’s eloralintide led to 20.1% weight loss after 48 weeks in a Phase II trial, exceeding analyst ...

As Trump pushes to cap international students, Harvard welcomes its most global class ever — 15% from abroad, 92 countries, ...

Strengthened balance sheet with private placement of up to $100 million to advance CMP-002, a first-in-class treatment for SYNGAP1-related disorders ...

Aligos Therapeutics, Inc. (Nasdaq: ALGS, 'Aligos”), a clinical stage biotechnology company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today ...

The Phase 2a data1 from initial dosing cohorts marks the first robust demonstration of an oral OX2R agonist addressing wakefulness needs across NT1 patients, who lack endogenous orexin, and the ...

THOUSAND OAKS, Calif., Nov. 4, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the third quarter of 2025.

Choose 8 to 16GB RAM, 512GB SSD, 13 to 14 inch HD, all day battery, 1080p webcam, Type C, Wi-Fi 6, strong India service for study, online classes and exam prep.

Narcolepsy type 1 is a chronic, rare neurological disease caused by the loss of orexin neurons in the brain. Orexin is a ...

Cash and investments are sufficient to fund current operations through Q2 2027, not including VenoValve commercialization and ...

Jay, a concerned parent, discovers his third grader missed crucial science classes for nine weeks. School promises a corrective plan for the rest of the year.